

PHARMACEUTICALS ([HTTP://YEARINREVIEW.CENMAG.ORG/TOPICS/PHARMACEUTICALS/](http://yearinreview.cenmag.org/topics/pharmaceuticals/))

AbbVie's Humira held onto top spot despite biosimilar threat

Drug is one of several biologics that dominated pharmaceutical sales in 2016

Ann M. Thayer (http://cen.acs.org/content/cen/static/about/staff_landing/bioamt.html?utm_source=InLine&utm_medium=InLine&utm_campaign=YIR16)

Among the top 10 pharmaceutical products in 2016, biologics beat out small molecules, and treatments for cancer and inflammation dominated the field. Holding the lead again was Humira, a monoclonal antibody targeting inflammatory and autoimmune diseases. At \$16.1 billion in sales, Humira outpaced the next-best-selling drug by more than \$6 billion.

In second place is Gilead Sciences' hepatitis C drug Harvoni, which grew rapidly after launching in late 2014. Sales cooled considerably—but not unexpectedly—this year as successful treatment has led to a decline in the patient population.

The public did get some good news last month when the World Health Organization declared that Zika is no longer a public health emergency. And while health experts stress that **efforts to address the virus** (http://cen.acs.org/articles/94/i8/Scientists-Scramble-Develop-Tools-Treatments-Zika-Virus.html?utm_source=InLine&utm_medium=InLine&utm_campaign=YIR16) must continue at full speed, government agencies, health groups, and industry have made some headway in figuring out how to combat it.

Among the firms behind the top products, Roche stands out for having three. But its leading cancer biologics—as well as Humira, Remicade, and Enbrel— will face **biosimilar competition** (http://cen.acs.org/articles/94/i29/Two-biosimilars-US-panels-nod.html?utm_source=InLine&utm_medium=InLine&utm_campaign=YIR16).


TOP 10 PRODUCTS

AbbVie's Humira retained the top spot while Gilead's sales of Harvoni faded

DRUG NAME	TYPE	MARKETER	INDICATION	2016 SALES (\$ BILLIONS)	% CHANGE FROM 2015
Humira	Antibody	AbbVie, Eisai	Inflammation	16.1	13
Harvoni	Small molecule	Gilead Sciences	Hepatitis C	9.9	-29
Enbrel	Protein	Amgen, Pfizer	Inflammation	8.7	0
Remicade	Antibody	Janssen, Merck & Co.	Inflammation	8.5	1
Rituxan	Antibody	Roche	Cancer	7.4	4
Revlimid	Small molecule	Celgene	Cancer	7.0	21
Herceptin	Antibody	Roche	Cancer	6.9	5
Avastin	Antibody	Roche, Chugai	Cancer	6.9	1
Lantus	Peptide	Sanofi	Diabetes	6.2	-11
Januvia/ Janumet	Small molecule	Merck & Co.	Diabetes	6.1	2

Note: Estimated sales are based on company statements and C&EN calculations.

Share this:

 (<http://yearinreview.cenmag.org/abbvies-humira-held-onto-top-spot-despite-biosimilar-threat/?share=facebook&nb=1>)

2



(http://cen.acs.org) **YEAR IN REVIEW (/)**

2016

Jump to

Behind the EpiPen (http://yearinreview.cenmag.org/behind-the-epipen/)

Zika response in full gear (http://yearinreview.cenmag.org/zika-response-in-full-gear/)

After the upset

AbbVie's Humira held onto top spot despite biosimilar threat (http://yearinreview.cenmag.org/abbvies-humira-held-onto-top-spot-despite-biosimilar-threat/)

After the upset (http://yearinreview.cenmag.org/after-the-upset/)

Eteplirsen controversy hit FDA (http://yearinreview.cenmag.org/eteplirsen-controversy-hit-fda/)

comment

Pharmaceutical firms saw mixed year in 2016 (http://yearinreview.cenmag.org/pharmaceutical-firms-saw-mixed-year-in-2016/)

Moonshot mania (http://yearinreview.cenmag.org/moonshot-mania/)

Biotech firms managed to go public in rocky year (http://yearinreview.cenmag.org/biotech-firms-managed-to-go-public-in-rocky-year/)

Breakup of Pfizer and Allergan shaped the year (http://yearinreview.cenmag.org/breakup-of-pfizer-and-allergan-shaped-the-year/)

e-mail

A focus on data (http://yearinreview.cenmag.org/a-focus-on-data/)

P O S T

Notify me of follow-up comments by email.

Notify me of new posts by email.

 (http://www.facebook.com/CENews)

 (http://twitter.com/cenmag)


TOP

CHEMICAL & ENGINEERING NEWS (HTTP://CEN.ACS.ORG)

© 2016 CHEMICAL & ENGINEERING NEWS

AMERICAN CHEMICAL SOCIETY (HTTP://ACS.ORG)